Why relentless innovation is Pro Medicus’ biggest opportunity and risk

HIGHLIGHTS

• Pro Medicus (ASX: PME) has garnered significant market attention in recent years, emerging as a growth stock standout
• The company's share price has soared from just above $4 in 2017 to a high exceeding $111, despite a recent sharp selloff, reflecting its remarkable growth trajectory alongside record results
• Co-founder and CEO Dr. Sam Hupert, far from stepping back, remains deeply engaged in the industry, declaring this as the prime time to be involved
• He sees artificial intelligence as a complementary force in healthcare imaging, capable of elevating standards further
• In an interview, Hupert discusses recent major contract wins and the future pipeline, as well as the company's approach to collaborating with thought leaders to expand opportunities